Neurocrine Biosciences Current Valuation vs. Revenue
| N1BI34 Stock | 38.16 0.65 1.73% |
For Neurocrine Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neurocrine Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neurocrine Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neurocrine Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neurocrine Biosciences over time as well as its relative position and ranking within its peers.
Neurocrine |
Neurocrine Biosciences Revenue vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Neurocrine Biosciences's current stock value. Our valuation model uses many indicators to compare Neurocrine Biosciences value to that of its competitors to determine the firm's financial worth. Neurocrine Biosciences is rated top company in current valuation category among its peers. It also is rated top company in revenue category among its peers totaling about 0.02 of Revenue per Current Valuation. The ratio of Current Valuation to Revenue for Neurocrine Biosciences is roughly 51.34 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Neurocrine Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neurocrine Biosciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Neurocrine Current Valuation vs. Competition
Neurocrine Biosciences is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers-Specialty & Generic industry is now estimated at about 4.4 Trillion. Neurocrine Biosciences claims roughly 58.19 Billion in current valuation contributing just under 2% to equities under Drug Manufacturers-Specialty & Generic industry.
Neurocrine Revenue vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Neurocrine Biosciences |
| = | 58.19 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Neurocrine Biosciences |
| = | 1.13 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Neurocrine Revenue vs Competition
Neurocrine Biosciences is rated top company in revenue category among its peers. Market size based on revenue of Drug Manufacturers-Specialty & Generic industry is now estimated at about 293.24 Billion. Neurocrine Biosciences adds roughly 1.13 Billion in revenue claiming only tiny portion of equities under Drug Manufacturers-Specialty & Generic industry.
Neurocrine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Neurocrine Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neurocrine Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neurocrine Biosciences' important profitability drivers and their relationship over time.
Use Neurocrine Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurocrine Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will appreciate offsetting losses from the drop in the long position's value.Neurocrine Biosciences Pair Trading
Neurocrine Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Neurocrine Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurocrine Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurocrine Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurocrine Biosciences to buy it.
The correlation of Neurocrine Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurocrine Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurocrine Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurocrine Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Neurocrine Biosciences position
In addition to having Neurocrine Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Management Thematic Idea Now
Health Management
Major hospitals and healthcare providers. The Health Management theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Neurocrine Stock
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:Check out Correlation Analysis. For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
To fully project Neurocrine Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Neurocrine Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Neurocrine Biosciences' income statement, its balance sheet, and the statement of cash flows.